A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.

Abstract

PURPOSE Bcl-2 is a negative prognostic indicator in prostate cancer, implicated in the development of androgen independence and treatment resistance, and is overexpressed in hormone-refractory prostate cancer (HRPC). Genasense is a phosphorothioate antisense oligonucleotide complementary to the bcl-2 mRNA open reading frame that in preclinical studies has… (More)

Topics

6 Figures and Tables

Cite this paper

@article{Chi2001API, title={A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.}, author={Kim N. Chi and Michelle Gleave and Richard Klasa and Noreen E. Murray and C. Bryce and Daniel E Lopes de Menezes and Susan D'Aloisio and Anthony William Tolcher}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2001}, volume={7 12}, pages={3920-7} }